Despite the rapid innovation of machine learning, correct protocols to ensure compliance and trustworthiness must be considered.
Michelle Marlborough
Advertisement
Chief product officer, AiCure, LLC
Articles by Michelle Marlborough
Advertisement
Latest Updated Articles
Why Machine Learning's Potential in Pharma Relies on Its TransparencyPublished: April 21st 2022 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
2
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
3
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
4
FDA Approves Expanded Indication of Jaypirca for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
5
